Volume 30, Number 10—October 2024
Research
Economic Analysis of National Program for Hepatitis C Elimination, Israel, 20231
Yuval Dadon
, Francis B. Mimouni, Ariella Toren, Tal Morgenstern, Lior Barak, and Joseph Mendlovic
, Francis B. Mimouni, Ariella Toren, Tal Morgenstern, Lior Barak, and Joseph Mendlovic
Table 1
Distribution of identified risk groups by HMOs in an economic analysis of a national program for hepatitis C elimination, Israel, 2023*
| HMO no. | At-risk persons† | Immigrants‡ | Total at-risk persons | Screened for HCV | Serology |
|||
|---|---|---|---|---|---|---|---|---|
| Testing pending | Positive | Seropositive + PCR-positive | % Viremia | |||||
| 1 |
73,023 (8.4) |
859 (3.2) |
73,882 (8.6) |
51,891 (70.2) |
21,991 |
2,396 (4.6) |
748 (31) |
1.4 |
| 2 |
113,982 (13.2) |
1,680 (6.5) |
114,426 (13.2) |
50,387 (44.0) |
64,039 |
1,545 (3.1) |
235 (15) |
0.5 |
| 3 |
318,380 (36.8) |
6,621 (25.5) |
325,001 (37.6) |
163,386 (50.3) |
161,615 |
9,795 (6.0) |
5,614 (57) |
3.4 |
| 4 |
359,997 (41.6) |
16,844 (64.8) |
350,600 (40.6) |
289,419 (82.5) |
61,181 |
10,625 (3.7) |
6,782 (64) |
2.3 |
| Total | 865,382 | 26,004 | 863,909 | 555,083 (64.3) | 308,826 (35.7) | 24,361 (4.4) | 13,379 (54.9) | 2.4 |
*Values were assessed by phase of screening status, prevalence of HCV serology and viremia in 4 HMOs. Values are no. (%) except as indicated. HCV, hepatitis C virus; HMO, health maintenance organization. †Data on at-risk persons included country of birth. ‡Persons who immigrated to Israel from Russia and Ukraine during the immigration wave of 2022 due to the Russia–Ukraine war.
1Preliminary results from this study were presented at the Israel National Institute for Health Policy Research conference; May 31, 2023; Tel Aviv, Israel.
Page created: August 21, 2024
Page updated: September 23, 2024
Page reviewed: September 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.